Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials Momentum

Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries

Ticker	Company	Price	Volume	Vol 1d %	SMA 10	SMA 20	SMA 50	SMA 100	SMA 200	RSI	Stochastic %K	Stochastic %D	StochRSI %K	StochRSI %D	MACD	MACD Signal	MACD Histogram	Beta
GRFS	GRIFOLS SA	$9.48	405,000	6.02%	9.21	9.11	8.92	9.37	8.94	63.54	80.56	78.58	71.95	70.69	0.11	0.08	0.03	0.76
LLY	ELI LILLY & CO	$1,108.09	4,653,000	72.91%	1,075.35	1,056.47	1,012.66	890.08	831.54	64.95	53.44	57.25	47.02	48.96	19.66	21.36	-1.70	0.59
GILD	GILEAD SCIENCES INC	$124.35	6,175,000	2.27%	123.20	122.31	122.81	119.19	113.98	54.10	42.32	35.58	41.58	29.95	-0.09	0.03	-0.13	0.42
GSK	GSK PLC	$50.62	5,204,000	-12.15%	49.42	48.99	47.89	44.71	41.43	66.47	68.74	73.95	73.27	67.96	0.65	0.57	0.08	0.35
BMY	BRISTOL MYERS SQUIBB CO	$56.72	18,042,000	7.60%	54.36	53.66	49.94	47.86	48.44	71.58	70.77	58.94	47.30	20.42	1.37	1.46	-0.09	0.30
AMGN	AMGEN INC	$341.64	3,599,000	32.17%	330.42	326.49	325.89	307.00	297.99	62.44	61.27	54.05	56.60	42.14	1.55	1.12	0.43	0.45
MRK	MERCK & CO INC	$108.60	16,322,000	12.73%	106.76	103.28	97.49	90.96	85.87	70.57	86.79	87.87	93.95	86.65	2.96	2.77	0.19	0.29
AZN	ASTRAZENECA PLC	$95.16	6,615,000	4.58%	92.74	91.76	89.31	85.08	78.07	67.27	74.20	66.79	69.03	46.69	1.15	1.01	0.14	0.44
SNY	SANOFI	$48.37	3,023,000	-29.20%	48.30	48.21	49.42	49.04	49.77	47.92	50.43	49.74	56.14	51.98	-0.30	-0.35	0.06	0.34
AMRN	AMARIN CORP PLC	$14.03	45,000	-29.69%	13.80	13.91	15.32	16.03	14.28	44.76	44.87	36.03	80.73	77.10	-0.49	-0.58	0.09	1.14
OGN	ORGANON & CO	$8.19	7,157,000	-17.00%	7.37	7.20	7.19	8.56	9.46	70.35	82.24	75.62	100.00	100.00	0.09	-0.06	0.15	0.80
ABBV	ABBVIE INC	$233.42	10,284,000	12.38%	228.46	226.65	226.51	223.55	206.35	58.16	46.79	48.23	45.50	41.89	0.37	0.24	0.13	0.36
JNJ	JOHNSON & JOHNSON	$207.49	7,546,000	-6.93%	206.66	207.52	201.02	191.66	174.77	55.45	37.98	32.09	18.30	10.02	1.13	1.84	-0.70	0.21
NVS	NOVARTIS AG	$141.98	2,003,000	-39.04%	139.37	136.71	131.63	129.57	122.03	71.69	81.31	78.21	62.07	50.18	2.57	2.31	0.26	0.34
PFE	PFIZER INC	$25.28	51,347,000	0.79%	25.10	25.31	25.18	25.03	24.47	50.61	30.84	23.10	66.18	45.64	-0.04	-0.04	0.00	0.40
BIIB	BIOGEN INC	$186.91	2,122,000	0.33%	177.94	175.91	169.91	156.54	141.96	68.62	82.42	77.09	78.76	76.17	2.76	2.30	0.46	0.71
SCLX	SCILEX HOLDING CO	$13.35	86,000	101.88%	13.20	14.57	17.06	18.58	13.10	38.52	30.68	25.03	82.34	63.68	-1.31	-1.29	-0.02	0.46
MIRA	MIRA PHARMACEUTICALS INC	$1.48	96,000	28.00%	1.51	1.51	1.49	1.44	1.36	48.42	16.00	18.67	3.96	5.50	0.00	0.01	-0.01	1.69
MDCX	MEDICUS PHARMA LTD	$1.57	186,000	-6.53%	1.55	1.69	1.99	2.16	2.86	39.26	25.85	24.16	88.77	82.38	-0.13	-0.15	0.01	0.57
NSRX	NASUS PHARMA LTD	$6.78	2,800	-12.50%	7.60	7.17	7.28	7.55	N/A	44.90	35.75	46.02	35.85	47.02	0.12	0.12	0.01	-0.21

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jan 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 38, which is -1 points lower than the general drug manufacturer industry average of 39. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 14 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 20.76% over the past year, underperforming other general drug manufacturer stocks by -12 percentage points.

Grifols Sa has an average 1 year price target of $10.00, an upside of 5.49% from Grifols Sa's current stock price of $9.48.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 56, which is 17 points higher than the general drug manufacturer industry average of 39.

LLY passed 22 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 43.3% over the past year, overperforming other general drug manufacturer stocks by 11 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,120.71, an upside of 1.14% from Eli Lilly & Co's current stock price of $1,108.09.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 17 analysts covering Eli Lilly & Co, 64.71% have issued a Strong Buy rating, 17.65% have issued a Buy, 17.65% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 58, which is 19 points higher than the general drug manufacturer industry average of 39.

GILD passed 21 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 37.21% over the past year, overperforming other general drug manufacturer stocks by 5 percentage points.

Gilead Sciences has an average 1 year price target of $136.29, an upside of 9.6% from Gilead Sciences's current stock price of $124.35.

Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Gilead Sciences, 64.29% have issued a Strong Buy rating, 21.43% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.57%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.73%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

2. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 4.15%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.73%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

3. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 3.4%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.73%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 99.4% indicates that its dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 2.86% in the last day, and up 3% over the last week. Bristol Myers Squibb Co was the among the top gainers in the drug manufacturers - general industry, gaining 4.23% yesterday.

Bristol-Myers Squibb shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $46 to $65.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 33 points higher than the general drug manufacturer industry average of 38. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -47.9% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -80 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 33 points higher than the general drug manufacturer industry average of 38. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 22.04% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -10 percentage points.

3. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 43, which is 5 points higher than the general drug manufacturer industry average of 38. It passed 3 out of 7 valuation due diligence checks.

Merck & Co's stock has gained 7.5% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -25 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 2.34% over the next year.

42.11% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 26.32% of general drug manufacturer stocks are rated B (Buy), 21.05% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 47.31x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.